An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Completed
The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/18/2014
Locations: Not set, Cleveland, Ohio +1 locations
Conditions: Ovarian Cancer
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexamethasone is more effective with or without thalidomide in treating multiple myeloma. PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or without thalidomide i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2014
Locations: Ireland Cancer Center, Cleveland, Ohio +3 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
Completed
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2014
Locations: Gabrail Cancer Center, Canton, Ohio +8 locations
Conditions: Multiple Myeloma
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for acute lymphoblastic leukemia. PURPOSE: Phase III trial to determine the effectiveness of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/18/2014
Locations: Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio
Conditions: Leukemia
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Bone marrow transplantation allows the doctor to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy with or without donor bone marrow transplantation in treating infants who have previously untreated acute lymphobla... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
02/18/2014
Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +3 locations
Conditions: Leukemia
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Terminated
This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP). The primary hypothesis is that patients treated with high-dose dexamethasone will obtain a more durable remission than patients treated with prednisone.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
01/02/2014
Locations: Case Western Reserve University, Cleveland, Ohio +1 locations
Conditions: Immune Thrombocytopenic Purpura
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
Unknown
RATIONALE: Hyperbaric oxygen may increase blood flow and decrease swelling in areas of the brain damaged by radiation therapy. Giving hyperbaric oxygen therapy together with dexamethasone may be an effective treatment for radiation necrosis of the brain. PURPOSE: This randomized clinical trial is studying how well hyperbaric oxygen therapy works in treating patients with radiation necrosis of the brain.
Gender:
ALL
Ages:
All
Trial Updated:
12/17/2013
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Radiation Toxicity
Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
Completed
This study is being done to determine the efficacies of two preventative drug combinations for postoperative nausea and vomiting in patients undergoing neurosurgery. The aim of this study is to compare the efficacy of using aprepitant instead of ondansetron in combination with dexamethasone and promethazine for post-operative nausea and vomiting prophylaxis. By completing this comparison study investigators will determine the most efficacious drug combination which will allow us to enhance the o... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/08/2013
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Postoperative Nausea and Vomiting (PONV), Nausea
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Completed
Palonosetron is different from ondansetron because it stays in the body longer and may prevent nausea and vomiting for a longer period of time than ondansetron. It is standard practice to use dexamethasone and aprepitant with either ondansetron or palonosetron to prevent nausea and vomiting caused by highly emetogenic chemotherapy. Although these combinations are commonly used, they have never been compared to each other. The purpose of this study is to record the amount of nausea and vomiting,... Read More
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
10/13/2013
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Malignant Neoplasm
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
08/23/2013
Locations: Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio +2 locations
Conditions: Leukemia
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
08/21/2013
Locations: Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio +2 locations
Conditions: Leukemia
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin, vincristine, and dexamethasone in treating patients with newly diagnosed or previously treated multiple myeloma.
Gender:
ALL
Ages:
All
Trial Updated:
07/17/2013
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
Conditions: Multiple Myeloma and Plasma Cell Neoplasm